Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following does NOT induce microsomal enzymes?

Cimetidine. **Explanation:** The core concept tested here is the distinction between **Enzyme Inducers** and **Enzyme Inhibitors**. Microsomal enzymes (primarily the Cytochrome P450 system in the liver) are responsible for the metabolism of many drugs. **1. Why Cimetidine is the correct answer:** Cimetidine is a potent **Enzyme Inhibitor**. It binds to the heme iron of the CYP450 system, reducing the metabolic activity of the liver. This leads to decreased clearance and increased plasma concentrations of co-administered drugs (like Warfarin or Theophylline), potentially causing toxicity. **2. Why the other options are incorrect:** * **Phenobarbitone:** A classic, potent inducer of CYP450 enzymes. It increases the synthesis of microsomal enzymes, accelerating the metabolism of itself and other drugs. * **Rifampicin:** One of the most powerful known enzyme inducers. It significantly reduces the half-life of drugs like oral contraceptives, often leading to therapeutic failure. * **Griseofulvin:** An antifungal agent known to induce hepatic microsomal enzymes, particularly affecting the metabolism of Warfarin. **High-Yield Clinical Pearls for NEET-PG:** To remember these for the exam, use these popular mnemonics: * **Enzyme Inducers (GPRS Cell Phone):** **G**riseofulvin, **P**henytoin/Phenobarbitone, **R**ifampicin, **S**moking, **C**arbamazepine. * **Enzyme Inhibitors (VITAMIN K):** **V**alproate, **I**soniazid, **T**erfenadine, **A**miodarone, **M**ethylphenidate, **I**traconazole, **N**ight (Grapefruit) juice, **K**etoconazole (**C**imetidine and **E**rythromycin are also critical inhibitors). **Note:** Cimetidine also has anti-androgenic side effects (gynecomastia), making it a frequent topic in NEET-PG pharmacology questions.

Q: Which of the following cephalosporins does not require dose modifications even in the presence of decreased GFR?

Cefoperazone. ### Explanation **Correct Answer: B. Cefoperazone** **1. Why Cefoperazone is Correct:** The primary mechanism for the elimination of most cephalosporins is renal excretion via glomerular filtration and tubular secretion. However, **Cefoperazone** and **Ceftriaxone** are notable exceptions. These drugs are primarily excreted through the **biliary tract (feces)** rather than the kidneys. Because their clearance is not dependent on the Glomerular Filtration Rate (GFR), they do not require dose adjustment in patients with renal impairment or renal failure. **2. Why the Other Options are Incorrect:** * **A. Cefepime:** A 4th-generation cephalosporin primarily excreted unchanged by the kidneys. Dose reduction is mandatory in renal insufficiency to prevent neurotoxicity (e.g., encephalopathy, seizures). * **C. Cefotaxime:** A 3rd-generation cephalosporin excreted mainly via the renal route. It requires dose modification when GFR falls below 20 mL/min. * **D. Cefuroxime:** A 2nd-generation cephalosporin that is almost entirely excreted by the kidneys. Accumulation occurs in renal failure, necessitating dose adjustments. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "Biliary Duo":** Remember **Ceftriaxone** and **Cefoperazone** as the two cephalosporins that are primarily eliminated in bile. * **Disulfiram-like Reaction:** Cefoperazone contains a **methylthiotetrazole (MTT) side chain**, which can cause a disulfiram-like reaction with alcohol and hypoprothrombinemia (bleeding risk due to Vitamin K antagonism). * **Pseudomonas Coverage:** Cefoperazone and Ceftazidime are 3rd-generation cephalosporins with specific activity against *Pseudomonas aeruginosa*. * **Rule of Thumb:** For almost all other beta-lactams (except Nafcillin/Oxacillin), "If the Kidneys fail, lower the scale (dose)."

Q: When the same dose of a drug is repeated at half-life intervals, after how many half-lives is the steady-state (plateau) plasma drug concentration reached?

4-5 half-lives. ### Explanation **Concept of Steady State Concentration ($C_{ss}$)** Steady state is reached when the rate of drug administration equals the rate of drug elimination. When a drug is administered at fixed intervals (usually equal to its half-life), the plasma concentration rises in a predictable, exponential fashion. **Why 4-5 half-lives is correct:** The accumulation of a drug follows first-order kinetics. After each half-life, the drug concentration reaches a specific percentage of the ultimate steady-state level: * 1 Half-life: 50% of $C_{ss}$ * 2 Half-lives: 75% of $C_{ss}$ * 3 Half-lives: 87.5% of $C_{ss}$ * **4 Half-lives: 93.75% of $C_{ss}$** * **5 Half-lives: 96.875% of $C_{ss}$** In clinical practice, reaching >90-95% of the plateau is considered achieving steady state. Therefore, **4 to 5 half-lives** is the standard duration required. **Analysis of Incorrect Options:** * **A (2-3 half-lives):** At this stage, the drug has only reached 75-87.5% of its plateau. The concentration is still rising significantly and has not stabilized. * **C & D (6-10 half-lives):** While the drug technically continues to approach 100% mathematically, the incremental increase after 5 half-lives is clinically negligible. **High-Yield Clinical Pearls for NEET-PG:** 1. **Elimination Rule:** Just as it takes 4-5 half-lives to reach steady state, it also takes approximately **4-5 half-lives for a drug to be completely eliminated** from the body after stopping the dose. 2. **Independence of Dose:** The time to reach steady state depends **only on the half-life**, not on the dose or the frequency of administration (though the *level* of the plateau depends on the dose). 3. **Loading Dose:** To achieve the steady-state concentration immediately without waiting for 4-5 half-lives, a **Loading Dose** is administered.

Q: When atrial fibrillation persists despite digoxin therapy, an inadequate digoxin dose is suspected. Plasma levels of digoxin for confirmation are typically drawn after a certain interval following the last dose. Considering pharmacokinetic principles, which factor is most crucial for determining this appropriate sampling time?

Rate of distribution. **Explanation:** The correct answer is **Rate of distribution (Option B)**. This is a classic pharmacokinetic concept essential for drugs that follow a **two-compartment model**, such as digoxin. Digoxin has a prolonged distribution phase (6–8 hours). After administration, the drug initially remains in the central compartment (blood) before moving into the peripheral compartment (tissues like the myocardium). Since the pharmacological effect of digoxin occurs at the tissue level, plasma levels drawn during the distribution phase will be falsely elevated and will not correlate with the drug’s clinical effect or toxicity. Therefore, sampling must be delayed until the **distribution equilibrium** is reached to ensure the plasma concentration reflects the tissue concentration. **Why other options are incorrect:** * **Rate of absorption (A):** While absorption determines how fast a drug enters the blood, it does not dictate the equilibrium between blood and the target organ (heart). * **Rate of clearance (C) and Elimination (D):** These factors determine the **half-life** and the time required to reach **steady-state** (usually 4–5 half-lives). While they influence the maintenance dose, they do not determine the specific timing of a post-dose sample (trough level) as critically as the distribution phase does for digoxin. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** For Digoxin, blood should be drawn at least **6 to 8 hours** after the last dose. * **Volume of Distribution ($V_d$):** Digoxin has a very high $V_d$ (~7 L/kg) because it binds extensively to skeletal muscle. * **Therapeutic Window:** Narrow (0.5–2.0 ng/mL). * **Toxicity Predisposition:** Hypokalemia, hypomagnesemia, and hypercalcemia increase the risk of digoxin toxicity.

Q: Which of the following is NOT a prodrug?

Lisinopril. The correct answer is **Lisinopril**. A **prodrug** is a pharmacologically inactive compound that must undergo metabolic conversion (usually in the liver) to become an active drug [2], [4]. **1. Why Lisinopril is the correct answer:** Most ACE inhibitors are prodrugs (esters) designed to improve oral bioavailability [4]. However, **Lisinopril** and **Captopril** are the two primary exceptions; they are already in their active form and do not require hepatic activation [1], [3]. This makes them preferred in patients with hepatic impairment. **2. Analysis of Incorrect Options:** * **Enalapril:** It is a classic prodrug converted by hepatic esterases into its active metabolite, **Enalaprilat** [4]. (Note: Enalaprilat is available only intravenously because it has poor oral absorption). * **Levodopa:** It is the metabolic precursor to **Dopamine**. Levodopa can cross the blood-brain barrier, whereas dopamine cannot. It is converted to active dopamine by the enzyme DOPA decarboxylase. * **Sulindac:** An NSAID of the indene derivative class. It is an inactive sulfoxide that must be reduced to an active **sulfide** metabolite in the body. **High-Yield Clinical Pearls for NEET-PG:** * **ACE Inhibitor Mnemonic:** All ACE inhibitors are prodrugs **EXCEPT** Lisinopril and Captopril [1]. * **Active Metabolites:** Always remember that **Enalaprilat** is the active form of Enalapril [4], and **Foscarnet** is an example of an antiviral that is NOT a prodrug (unlike Acyclovir). * **Advantage of Prodrugs:** They are often designed to increase absorption (e.g., Valacyclovir), decrease gastrointestinal toxicity (e.g., Sulindac), or ensure site-specific delivery (e.g., Levodopa) [2], [4].

Q: Which of the following is a prodrug of cetirizine?

Hydroxyzine. **Explanation:** The correct answer is **Hydroxyzine**. **Why Hydroxyzine is correct:** Hydroxyzine is a first-generation H1-receptor antagonist. It undergoes extensive hepatic metabolism via the enzyme alcohol dehydrogenase to form its active carboxylic acid metabolite, **Cetirizine**. Since Cetirizine is the active form derived from the metabolic conversion of Hydroxyzine, Hydroxyzine acts as the prodrug. Cetirizine itself is a second-generation antihistamine known for being less sedative because it is a zwitterion and does not readily cross the blood-brain barrier. **Analysis of Incorrect Options:** * **Terfenadine:** This was the first non-sedating antihistamine. It is actually the prodrug of **Fexofenadine**. Terfenadine was withdrawn from the market because it caused QTc prolongation and *Torsades de Pointes* when its metabolism was inhibited (e.g., by erythromycin or ketoconazole). * **Fexofenadine:** This is the active metabolite of Terfenadine. It is a third-generation antihistamine and is not a prodrug. * **Azelastine:** This is a second-generation antihistamine primarily used as a nasal spray for allergic rhinitis or ophthalmic drops for conjunctivitis. It is an active drug, not a prodrug. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolite Pairs:** Remember **Terfenadine → Fexofenadine**, **Loratadine → Desloratadine**, and **Hydroxyzine → Cetirizine**. * **Safety Profile:** Cetirizine is unique among second-generation antihistamines as it may cause mild sedation in some patients compared to Fexofenadine (the "most" non-sedating). * **Pharmacokinetics:** Most second-generation antihistamines have long half-lives, allowing for once-daily dosing.

Q: Which of the following is a CYP-450 inducer?

Phenobarbitone. **Explanation:** The Cytochrome P450 (CYP450) enzyme system is the primary pathway for drug metabolism in the liver. Drugs that interact with this system are classified as either **inducers** or **inhibitors**. **Why Phenobarbitone is Correct:** Phenobarbitone is a classic **CYP450 inducer**. It works by increasing the synthesis of microsomal enzymes (via activation of nuclear receptors like CAR). This leads to an increased rate of metabolism for co-administered drugs (e.g., Warfarin, Oral Contraceptive Pills), resulting in **decreased plasma concentrations** and potential therapeutic failure. **Why Other Options are Incorrect:** * **Cimetidine:** This is a potent **CYP450 inhibitor**. It binds to the heme iron of the CYP450 enzyme, reducing the metabolism of other drugs (e.g., Theophylline, Phenytoin), which can lead to toxicity. * **Ketoconazole:** This is a well-known antifungal that acts as a strong **CYP450 inhibitor** (specifically CYP3A4). It is often used in pharmacology questions to illustrate drug-drug interactions that increase the risk of arrhythmias (e.g., when taken with Terfenadine). **High-Yield Clinical Pearls for NEET-PG:** To remember these for the exam, use these popular mnemonics: 1. **Enzyme Inducers (GPRS Cell Phone):** **G**riseofulvin, **P**henytoin, **R**ifampicin, **S**moking, **C**arbamazepine, **P**henobarbitone. 2. **Enzyme Inhibitors (VITAMIN K):** **V**alproate, **I**soniazid, **T**amoxifen, **A**miodarone, **M**acrolides (except Azithromycin), **I**ndinavir, **N**etupitant, **K**etoconazole (and Cimetidine/Grapefruit juice). *Note:* Enzyme **induction** usually takes 1–2 weeks to manifest (requires protein synthesis), whereas enzyme **inhibition** occurs almost immediately.

Q: What does the plasma concentration versus time graph indicate?

Bioavailability. ***Bioavailability*** - The **plasma concentration versus time graph** is primarily used to calculate bioavailability by comparing the **area under the curve (AUC)** between different routes of administration (oral vs IV). - **Bioavailability (F)** is determined using the formula: F = AUC_oral / AUC_IV × Dose_IV / Dose_oral, making this graph essential for **bioequivalence studies**. *Half-life* - **Half-life** is derived from the **elimination phase slope** of the plasma concentration curve, not the overall graph comparison. - It represents the time required for plasma concentration to decrease by **50%** and is calculated from a single curve's declining phase. *Clearance* - **Clearance** is calculated using the formula **Dose/AUC** and represents the volume of plasma cleared per unit time. - While the graph provides AUC data needed for clearance calculation, the graph itself doesn't directly indicate clearance. *Elimination* - **Elimination rate constant** is determined from the **slope of the terminal elimination phase** of a single concentration-time curve. - The graph comparison between routes doesn't directly measure elimination kinetics but rather **absorption and bioavailability differences**.

Question 1

Which of the following does NOT induce microsomal enzymes?

Accepted Answer

Cimetidine

Answer

Griseofulvin

Answer

Rifampicin

Answer

Phenobarbitone

Question 2

Which of the following cephalosporins does not require dose modifications even in the presence of decreased GFR?

Accepted Answer

Cefoperazone

Answer

Cefipine

Answer

Cefotaxime

Answer

Cefuroxime

Question 3

When the same dose of a drug is repeated at half-life intervals, after how many half-lives is the steady-state (plateau) plasma drug concentration reached?

Accepted Answer

4-5 half-lives

Answer

2-3 half-lives

Answer

6-7 half-lives

Answer

8-10 half-lives

Question 4

When atrial fibrillation persists despite digoxin therapy, an inadequate digoxin dose is suspected. Plasma levels of digoxin for confirmation are typically drawn after a certain interval following the last dose. Considering pharmacokinetic principles, which factor is most crucial for determining this appropriate sampling time?

Accepted Answer

Rate of distribution

Answer

Rate of absorption

Answer

Rate of clearance

Answer

Rate of elimination

Question 5

Single dose aminoglycoside administration is more preferable than 8 hourly dosing because of which of the following?

Accepted Answer

Post-antibiotic effect

Answer

Minimum Inhibitory Concentration (MIC)

Answer

Increased perfusion of the renal cortex

Answer

None of the above

Question 6

Which of the following is false regarding spare receptors?

Accepted Answer

They are needed for binding a drug to achieve the maximum effect.

Answer

They respond to agonists only.

Answer

They do not alter maximal efficacy.

Answer

They can be detected by finding that EC50 < Kd for the agonist.

Question 7

Which of the following is NOT a prodrug?

Accepted Answer

Lisinopril

Answer

Enalapril

Answer

Levodopa

Answer

Sulindac

Question 8

Which of the following is a prodrug of cetirizine?

Accepted Answer

Hydroxyzine

Answer

Foxefenadone

Answer

Terfenadine

Answer

Azelastine

Question 9

Which of the following is a CYP-450 inducer?

Accepted Answer

Phenobarbitone

Answer

Cimetidine

Answer

Ketoconazole

Answer

All of the above

Question 10

What does the plasma concentration versus time graph indicate?

Accepted Answer

Bioavailability

Answer

Half-life

Answer

Clearance

Answer

Elimination

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?